Risk Factors for No-Reflow Phenomenon after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome

Abstract

Background: To explore risk factors for no-reflow phenomenon after percutaneous coronary intervention in patients with acute

Prediction of no‐reflow and major adverse cardiovascular events with a new scoring system in STEMI patients

“…In our study, age, EF, thrombus grade, Killip class, pain‐PCI time, stent length, and SS were found to be predictors of no‐reflow. T. Liang and coworkers observed that the development of no‐reflow was higher in advanced age patients . A higher incidence of diffuse atherosclerosis, severe calcification, distal microvessel embolization, and microvascular diseases in elderly patients are thought to cause the development of no‐reflow .…”

“…T. Liang and coworkers observed that the development of no-reflow was higher in advanced age patients. 18 A higher incidence of diffuse atherosclerosis, severe calcification, distal microvessel embolization, and microvascular diseases in elderly patients are thought to cause the development of no-reflow. 19 Consistent with this, we showed that advanced age was an independent risk factor in the development of no-reflow.…”

Cardiovascular events associated with nicorandil administration prior to primary percutaneous coronary intervention in patients with acute ST-segment elevated myocardial infarction: a systematic review and meta-analysis

“…A small but significant proportion of PCI-treated patients will continue to manifest diminished myocardial reperfusion, which may ultimately result in cardiac arrest or acute heart failure. This is attributable to the complex pathophysiological mechanism of STEMI, individual comorbidities, and complications such as myocardial reperfusion injury and NRP [7,33], requiring further treatment to improve the patient's prognosis.…”

“…Analysis of the follow-up and total MACE showed a significant reduction in patients who received nicorandil compared with controls. NRP is an independent risk factor that can affect patient prognosis after PCI; it has been reported to have pathological factors [7] and is attributed to endothelial cell inflammation.…”

“…However, the clinical efficacy of PCI is not always as expected and is sometimes limited by post-PCI complications such as no-reflow phenomenon (NRP). NRP is a condition whereby effective reperfusion of damaged myocardial tissue is suboptimal even after PCI [7,8]. NRP has an incidence rate of 5-25% [7] and is associated with increased myocardial remodeling, left ventricular dysfunction, and mortality [9,10].…”